logo-loader

Clinigen Group expands its relationship with US giant

Last updated: 19:28 31 May 2018 AEST, First published: 16:19 31 May 2018 AEST

1527747979_shutterstock_168702206
The five-year tie-up will see the transfer of marketing authorisations from BMS to the UK company, a process that will be completed in the first half of next year

Clinigen Group PLC (LON:CLIN) has extended its relationship with Bristol-Myers Squibb (BMS) in a deal that will provide access to the latter's products in South Africa.

Clinigen's commercial medicines arm will lend local regulatory expertise, supply and distribution infrastructure and experience in managing licensed drugs there.

WATCH: Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

The five-year tie-up will see the transfer of marketing authorisations from BMS to the UK company, a process that will be completed in the first half of next year.

Growing basket of drugs 

Clinigen will then have 192 actively marketed specialist pharmaceutical and technology licensed products in Africa and Asia-Pacific.

The deal will "complement the group's growing basket of essential medicines", the company said.

Chief executive Shaun Chilton added: "[It] demonstrates the long and successful relationship we have built with BMS, which began with providing access to BMS' unlicensed products globally, and has grown with Clinigen's expansion into important future growth markets.

"Clinigen is increasingly becoming the partner of choice for pharmaceutical companies to license and distribute their products. 

"This agreement shows that our strategy for commercial medicines of adding regional commercial agreements to our existing portfolio of global products, a key strategic priority for the group, is working."

Shares up, but could they go higher

The shares rose 1.9% to 853p, valuing Clinigen at just over £1bn.

The City broker Numis reckons the stock is worth 1,208p. Analyst Stefan Hamill said: “The deal builds on a long-lasting relationship between Clinigen and BMS, starting in its management of BMS unlicensed medicines products globally.

“The importance of a major pharma company such as BMS entrusting its products to Clinigen in the region is that it should now provide Clinigen with a good case study to roll out a similar relationship with other such companies over time.

“The strategy is in some ways is analogous to Hikma's strategy in the Middle East and North Africa.”

 

 

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 31 minutes ago